Page last updated: 2024-11-10

thromboxane b3

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

thromboxane B3 : A member of the class of thromboxanes B that is (5Z,13E,17Z)-thromboxa-5,13,17-trien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5283140
CHEBI ID84444
SCHEMBL ID8820991
MeSH IDM0117402

Synonyms (21)

Synonym
9s,11,15s-trihydroxy-thromboxa-5z,13e,17z-trien-1-oic acid
txb3
thromboxane b3
LMFA03030006
(z)-7-[(2r,3s,4s)-4,6-dihydroxy-2-[(1e,3s,5z)-3-hydroxyocta-1,5-dienyl]oxan-3-yl]hept-5-enoic acid
71953-80-5
unii-s1wq5uny10
thromboxa-5,13,17-trien-1-oic acid, 9,11,15-trihydroxy-, (5z,9alpha,13e,15s,17z)-
s1wq5uny10 ,
CHEBI:84444
(5z,13e,15s,17z)-9beta,11,15-trihydroxythromboxa-5,13,17-trien-1-oic acid
SCHEMBL8820991
thromboxa-5,13,17-trien-1-oic acid, 9,11,15-trihydroxy-, (5z,9.alpha.,13e,15s,17z)-
5-heptenoic acid, 7-((2r,3s,4s)-tetrahydro-4,6-dihydroxy-2-((1e,3s,5z)-3-hydroxy-1,5-octadien-1-yl)-2h-pyran-3-yl)-, (5z)-
(5z)-7-((2r,3s,4s)-tetrahydro-4,6-dihydroxy-2-((1e,3s,5z)-3-hydroxy-1,5-octadien-1-yl)-2h-pyran-3-yl)-5-heptenoic acid
(5e)-7-{4,6-dihydroxy-2-[(1e,5e)-3-hydroxyocta-1,5-dien-1-yl]oxan-3-yl}hept-5-enoic acid
OYPPJMLKAYYWHH-NXJDUNGTSA-N
Q27157766
sr-01000946882
SR-01000946882-1
DTXSID501347454

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"To determine the efficacy of a novel and safer (for gastrointestinal tract) aspirin (aspirin-PC) in preclinical models of ovarian cancer, in vitro dose-response studies were performed to compare the growth-inhibitory effect of aspirin-PC versus aspirin on three human (A2780, SKOV3ip1, and HeyA8) and a mouse (ID8) ovarian cancer cell line over an 8-day culture period."( Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer.
Bottsford-Miller, JN; Dial, EJ; Dorniak, PL; Fang, D; Filant, J; Haemmerle, M; Hansen, JM; Hatakeyama, H; Hu, W; Huang, Y; Lichtenberger, LM; Lyons, Y; Pradeep, S; Previs, RA; Shen, F; Sood, AK; Taylor, M; Wagner, MJ, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
thromboxanes B
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Eicosanoid metabolism via lipooxygenases (LOX)040
Arachidonic acid metabolism via LOX (Lipooxygenase) pathway033

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (28.57)18.7374
1990's5 (35.71)18.2507
2000's1 (7.14)29.6817
2010's3 (21.43)24.3611
2020's1 (7.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.59 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (28.57%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (71.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]